Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.72 |
| ▸ | ESR1 | P03372 | 7/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377227 | 0.86 | RAB9A (0.76) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL9953323 | 0.86 | RAB9A (0.76) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30437013 | 0.85 | RAB9A (0.73) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL30942307 | 0.84 | RAB9A (0.72) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL20886963 | 0.84 | RAB9A (1.00) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL16291434 | 0.84 | RAB9A (0.72) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL20886926 | 0.84 | RAB9A (0.72) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL20886974 | 0.84 | RAB9A (0.72) | ESR2ESR1RAB9AGAASMN1; SMN2 | |
| SCHEMBL1795123 | 0.84 | ESR2 (1.00) | ESR2ESR1RAB9AFGFR1 | |
| SCHEMBL13912290 | 0.84 | RAB9A (0.72) | ESR2ESR1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| CN-1918128-B | fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| CN-1918128-A | Fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ESR2 625/4885ESR1 556/4885RAB9A 3792/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ESR2 625/4885ESR1 556/4885RAB9A 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.